Gil Morgan
Physician from Texas working in Medical Oncology. Proudly NIH, NCI & MDA trained. Believer that an ounce of prevention equals a pound of cure. Views are my own.
Last synced from Twitter Not synced yet
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
The Lancet Oncology 86d 2 tweets
With extended study follow-up, results from KEYNOTE-426 show that pembrolizumab plus axitinib continues to have superior clinical outcomes over sunitinib. These results continue to support the first-line treatment with pembrolizumab plus axitinib as...
1
Gil Morgan Just Out📣 📰 by & team Results from KEYNOTE4️⃣2️⃣6️⃣ show pembro+ axitinib continue to have superior clinical outcomes over sunitinib & support the 1️⃣st line treatment w/pembro + axitinib as SOC of advanced #RCC #KidneyCancer 86d
FDA grants nivolumab/cabozantinib combo priority review in kidney cancer
Urology Times 89d 1 tweets
The FDA is reviewing data from the phase 3 CheckMate-9ER trial, which showed that the combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.
4
Gil Morgan Just Out📢 🇺🇸grants nivolumab/cabozantinib combo priority review in #kidneyCancer based on data #CheckMate9ER presented at #ESMO20 by our 🚨Colleague ✅ Risk reduction of disease progression or death by4⃣9⃣% Vs Sutent 89d
COVID-19 in patients with cancer: managing a pandemic within a pandemic
Nature Reviews Clinical Oncology 95d 3 tweets
The coronavirus disease 2019 (COVID-19) pandemic has disrupted health care worldwide. Patients with cancer seem to be particularly susceptible to morbidities and mortality from this novel disease. No COVID-19-specific therapy currently seems to...
1
Gil Morgan Out📣on 📰 Patients with #cancer seem to be particularly susceptible to morbidities & mortality from #COVID19. The global🌎effects on routine cancer care will likely be felt for decades to come. 91d
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives
Nature Reviews Clinical Oncology 99d 3 tweets
Despite the introduction of novel therapies, lung cancer remains the leading cause of cancer-related mortality worldwide. Randomized controlled trials of low-dose CT-based lung cancer screening in high-risk populations have shown a reduction in...
1
Gil Morgan Just Out📣 📰 Role of CT #screening on #LungCancer related mortality reduction has been under debate for 5️⃣0️⃣yrs & is now an evidence-based reality. Great Review & proposal for SPIRAL: to define scope of future implementation research 96d
Welcome! You are invited to join a meeting: YO Mentorship session 7 - Social Media. After registering, you will receive a confirmation email about joining the meeting.
Zoom Video 98d 1 tweets
Welcome! You are invited to join a meeting: YO Mentorship session 7 - Social Media. After registering, you will receive a confirmation email about joining the meeting.
2
Gil Morgan TONIGHT‼️ As the Virtual Train to 🚂heads back to Europe🇪🇺for #ESMO20 Educational📚 WE make a STOP🚏in my home state of TEXAS🇺🇸for A Great Social Media Mentorship Session w/ & myself Warm invite to ALL to participate🤠 Register here 98d
ESMO Virtual Congress 2020: Registration
Esmo.org 188d 24 tweets
Register for the ESMO Virtual Congress 2020 - Science: 19-21 Sep 2020 | Education: 16-18 Sep 2020
2
Gil Morgan Dear Colleagues🌐 Reminder that #ESMO20 Educational Weekend Starts THIS FRIDAY October 16-October 18🗓️ We have a GREAT programme in store & cant wait to see y'all there👩‍⚕️👨‍⚕️ Huge Round of thanks to Always Keeping oncology #education accessible‼️ 99d
A roadmap for the early detection and diagnosis of cancer
The Lancet Oncology 105d 2 tweets
If we are to beat cancer, early detection and diagnosis are arguably the most effective means we have at our disposal. Progress during the past 40 years has transformed the prospects of people diagnosed with cancer in the UK, with survival doubling...
3
Gil Morgan Great commentary out in If we’re to beat cancer, early detection & diagnosis are arguably the most effective means we have. But, further improvements are greatly needed, because #cancer remains the leading cause of death in the UK 🇬🇧 105d
FDA approves nivolumab and ipilimumab for unresectable malignant pleur
U.S. Food and Drug Administration 109d 4 tweets
FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma
2
Gil Morgan Just Out📢 🇺🇸approves the combination of nivolumab plus ipilimumab as first-line treatment for adult patients with unresectable malignant pleural mesothelioma‼️ Based on efficacy results from #CHECKMATE743 #OncoAlert 🚨 109d
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC | NEJM
New England Journal of Medicine 109d 7 tweets
Original Article from The New England Journal of Medicine — Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
1
Gil Morgan Just Out📢at 📰 #IMpower110 sees that in 1⃣st line treatment of PDL1 selected patients with #NSCLC #lungcancer ✅Atezolizumab had significantly longer OS than platinum-based #chemotherapy, regardless of histologic type. #LCSM #OncoAlert 🚨 109d
2
Gil Morgan Out📣on the 📰 1️⃣st line Atezolizumab treatment results in significantly longer OS than platinum-based🧪#chemotherapy among patients w/ #NSCLC #LungCancer w/ high PD-L1 expression, regardless of histologic type #OncoAlert 🚨 #LCSM 104d
Burnout among cancer professionals during COVID-19
The Lancet Oncology 113d 2 tweets
Newly released results from two online surveys done by the European Society for Medical Oncology (ESMO) Resilience Task Force have outlined the extent to which the COVID-19 pandemic has affected burnout, job performance, and wellbeing in the global...
1
Gil Morgan Just Out📣Great article out on 📰on #Burnout among #cancer professionals during #COVID19 discussing the results from the Resilience Taskforce Surveys which were conducted with official collaboration with the 🚨Network‼️ 113d
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
Prnewswire.com 127d 1 tweets
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion...
1
Gil Morgan Just Out📣 🇺🇸grants premarket approval to Oncomine Dx Target🎯Test as a companion diagnostic to identify RET🧬fusion-positive, metastatic non-small cell #LungCancer #NSCLC patients candidates for pralsetinib #OncoAlert 🚨 127d
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
The Lancet Oncology 130d 15 tweets
tTMB-high status identifies a subgroup of patients who could have a robust tumour response to pembrolizumab monotherapy. tTMB could be a novel and useful predictive biomarker for response to pembrolizumab monotherapy in patients with previously...
2
Gil Morgan Just out📣 📰 KEYNOTE1️⃣5️⃣8️⃣suggests Tumor mutational burden could be a novel & useful predictive biomarker🎯for response to pembrolizumab🧪monotherapy in previously treated recurrent or metastatic advanced solid tumors #OncoAlert 🚨 130d
Pralsetinib Shows Clinical Activity in Multiple RET Fusion–Positive Tumors
ASCO Daily News 132d 1 tweets
1
Gil Morgan Just Out📢 Great article on News📰showcasing our 🚨 Super Star Colleagues & discussing how Pralsetinib has Shown Clinical Activity in Multiple🧬RET Fusion–Positive🎯Tumors #OncoAlert 🌐 132d
2020 US election and implications for cancer care
The Lancet Oncology 132d 1 tweets
As the USA enters the final weeks of the presidential election race, one clear message is coming through during the chaos of an ongoing pandemic, which continues to claim thousands of lives and destroy the economic livelihoods of millions...
1
Gil Morgan Dear colleagues, I try to stay as unpolitical as possible on social media but I saw this piece Just Out📣 at 📰which made me realize....leadership matters🇺🇸& it affects us all‼️ #OncoAlert 🚨 132d
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
Science Translational Medicine 139d 3 tweets
Chimeric antigen receptor (CAR) T cells are engineered to recognize specific antigens on tumor cells. In some cases, such as with the B cell antigen CD19, a naturally occurring antigen presents an effective target. In most cases, however, there is...
1
Gil Morgan Just Out📣on 📰 Promising Pre Clinical data out of shows combining oncolytic virus with #CART cell therapy Allows for Targeting 🎯& a more effective eradication of solid tumors compared to CAR T therapy alone‼️ #OncoAlert 🚨 133d
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma | NEJM
New England Journal of Medicine 137d 4 tweets
Original Article from The New England Journal of Medicine — Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
1
Gil Morgan Out📣at 📰 5️⃣year follow-up COMBI-AD in resected stage3️⃣ melanoma w/BRAF V600E or V600K🧬mutations ✅12 mo.adj therapy w/dabrafenib+trametinib results longer survival duration ✅w/o relapse/distant mets Vs placebo ✅No long term tox #OncoAlert 🚨 134d
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
New England Journal of Medicine 138d 10 tweets
Original Article from The New England Journal of Medicine — Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
1
Gil Morgan Just out📣on 📰 GEOMETRY trial sees Capmatinib has substantial antitumor activity in patients with advanced #NSCLC #LungCancer w/a MET exon 14 skipping mutation🧬particularly in those not treated previously🧪 #LCSM #OncoAlert🚨 137d
Progress in Cancer Research, Prevention, and Care | NEJM
New England Journal of Medicine 138d 8 tweets
Perspective from The New England Journal of Medicine — Progress in Cancer Research, Prevention, and Care
2
Gil Morgan Just Out📣on 📰from CMO Great perspective piece& podcast🎙summarizing 5️⃣0️⃣years of progress Vs #cancer. A must for all who wants to be uplifted by the progress in #CancerResearch #Prevention &Care! Thanks for the tip 138d
Physical Activity Does Not Lower the Risk of Lung Cancer
Cancer Research 138d 1 tweets
Observational studies have suggested that physical activity might lower the risk of lung cancer in former and current smokers, but not in never-smokers. Using genetic instruments for self-reported and accelerometer-measured physical activity traits...
1
Gil Morgan Just out📣at 📰 A new genetic🧬study provides little evidence that recommending physical 🏃‍♂️activity would help prevent #lungcancer in ever and never smokers #LCSM #OncoAlert 🚨 138d
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer | NEJM
New England Journal of Medicine 145d 26 tweets
Original Article from The New England Journal of Medicine — Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
2
Gil Morgan Just out📣on 📰 Efficacy of Selpercatinib🎯in RET🧬fusion➕#NSCLC By some amazing 🚨Colleagues & team: Congrats et al‼️ #LCSM #LungCancer 145d